Prexasertib
Information
- Drug Name
- Prexasertib
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung small cell carcinoma | MYC OVEREXPRESSION MYC OVEREXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 28490518 | Detail |
| lung small cell carcinoma | CHEK1 OVEREXPRESSION CHEK1 OVEREXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 28490518 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| A preclinical study to evaluate the efficacy of ta... | MYC | MYC OVEREXPRESSION MYC OVEREXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| A preclinical study to evaluate the efficacy of ta... | CHEK1 | CHEK1 OVEREXPRESSION CHEK1 OVEREXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04095221 | Active, not recruiting | Phase 1/Phase 2 | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | September 17, 2019 | September 2024 |
| NCT04023669 | Active, not recruiting | Phase 1 | Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | August 8, 2019 | October 2024 |
| NCT02514603 | Completed | Phase 1 | A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers | October 2015 | April 10, 2017 |
| NCT02555644 | Completed | Phase 1 | A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer | February 24, 2016 | January 14, 2019 |
| NCT02649764 | Completed | Phase 1 | Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | May 4, 2016 | July 12, 2022 |
| NCT02735980 | Completed | Phase 2 | A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer | May 11, 2016 | February 12, 2019 |
| NCT02778126 | Completed | Phase 1 | A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer | September 22, 2016 | July 27, 2017 |
| NCT01115790 | Completed | Phase 1 | A Phase 1 Study in Participants With Advanced Cancer | February 2010 | January 2016 |
| NCT02860780 | Completed | Phase 1 | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | August 10, 2016 | May 15, 2017 |
| NCT03057145 | Completed | Phase 1 | Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors | March 10, 2017 | June 9, 2021 |
| NCT03414047 | Completed | Phase 2 | A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | April 10, 2018 | October 3, 2020 |
| NCT03495323 | Completed | Phase 1 | A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors | May 16, 2018 | February 1, 2021 |
| NCT02808650 | Completed | Phase 1 | Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | February 27, 2017 | March 31, 2021 |
| NCT02124148 | Completed | Phase 1 | A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | June 18, 2014 | February 13, 2020 |
| NCT03735446 | Terminated | Phase 1 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | January 18, 2019 | March 29, 2019 |